Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpegerglucagon in Obese or Overweight Subjects With Comorbidities
NCT04167553Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing HM15136 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events at 12 weeks, Serum Amylase Levels at 12 weeks and 3 more. Started Aug 2019; status: completed.
02
Drugs
efpegerglucagon
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04167553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167553.